[go: up one dir, main page]

PL338982A1 - Drug for improving duration of muscle action or for treating muscular disorders or diseases - Google Patents

Drug for improving duration of muscle action or for treating muscular disorders or diseases

Info

Publication number
PL338982A1
PL338982A1 PL98338982A PL33898298A PL338982A1 PL 338982 A1 PL338982 A1 PL 338982A1 PL 98338982 A PL98338982 A PL 98338982A PL 33898298 A PL33898298 A PL 33898298A PL 338982 A1 PL338982 A1 PL 338982A1
Authority
PL
Poland
Prior art keywords
diseases
drug
duration
muscle action
muscular disorders
Prior art date
Application number
PL98338982A
Other languages
English (en)
Original Assignee
Astacarotene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL338982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astacarotene Ab filed Critical Astacarotene Ab
Publication of PL338982A1 publication Critical patent/PL338982A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)
PL98338982A 1997-09-04 1998-08-26 Drug for improving duration of muscle action or for treating muscular disorders or diseases PL338982A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
PCT/SE1998/001526 WO1999011251A1 (en) 1997-09-04 1998-08-26 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases

Publications (1)

Publication Number Publication Date
PL338982A1 true PL338982A1 (en) 2000-12-04

Family

ID=20408142

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98338982A PL338982A1 (en) 1997-09-04 1998-08-26 Drug for improving duration of muscle action or for treating muscular disorders or diseases

Country Status (13)

Country Link
US (1) US6245818B1 (xx)
EP (1) EP1011653B1 (xx)
JP (1) JP3660244B2 (xx)
AT (1) ATE230985T1 (xx)
AU (1) AU727349B2 (xx)
CA (1) CA2299366C (xx)
DE (1) DE69810784T2 (xx)
DK (1) DK1011653T3 (xx)
ES (1) ES2191329T3 (xx)
NO (1) NO20001087L (xx)
PL (1) PL338982A1 (xx)
SE (1) SE512531C2 (xx)
WO (1) WO1999011251A1 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001071D0 (sv) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
US7078040B2 (en) 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0003186D0 (sv) * 2000-09-07 2000-09-07 Astrazeneca Ab New process
US6900324B2 (en) 2000-09-07 2005-05-31 Astrazeneca Ab Process for preparing a substituted imidazopyridine compound
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7521584B2 (en) 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
EP2392562B1 (en) * 2002-07-29 2018-03-07 Cardax Pharma, Inc. Structural carotenoid analogs for the inhibition and amelioration of disease
AU2002329108A1 (en) * 2002-09-03 2004-03-29 Centro De Investigacion En Alimentacion Y Desarrollo A.C. Method of preparing chitosan microcapsules of astaxanthin and product thus obtained
US8034372B2 (en) * 2003-03-05 2011-10-11 Nestec, Ltd. Dietary supplement for athletic pets
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
WO2005041961A1 (en) * 2003-11-03 2005-05-12 Astrazeneca Ab Imidazo [1,2-a] pyridine derivatives for the treatment of silent gastro-esophageal reflux
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
ES2587652T3 (es) 2004-02-04 2016-10-26 Fuji Chemical Industry Co., Ltd. Astaxantina para mejorar la atrofia muscular
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2005102356A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060155150A1 (en) * 2004-10-01 2006-07-13 Lockwood Samuel F Methods for the synthesis of lutein
JP5196708B2 (ja) * 2005-02-04 2013-05-15 富士化学工業株式会社 アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
US20060270590A1 (en) 2005-03-29 2006-11-30 Lockwood Samuel F Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
US20090297492A1 (en) * 2008-05-30 2009-12-03 Yamaha Hatsudoki Kabushiki Kaisha Method for Improving Cognitive Performance
US10867701B1 (en) 2010-06-28 2020-12-15 Heinrich Anhold System and method for optimizing patient-specific intervention strategies using point of care diagnostics
JP5924592B2 (ja) * 2013-04-30 2016-05-25 株式会社ダイセル 抗疲労用組成物
CN112057420A (zh) * 2020-09-21 2020-12-11 中国科学院烟台海岸带研究所 一种虾青素喷剂及其制备方法、使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558372B1 (fr) 1984-01-25 1987-08-07 Oreal Composition medicamenteuse pour le traitement de l'acne
JP2619491B2 (ja) 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
JPH0665033A (ja) 1992-08-11 1994-03-08 Lion Corp 口腔用組成物
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
CA2210957A1 (en) 1995-02-03 1996-08-08 Basf Aktiengesellschaft The use of carotenoids for producing drugs for the treatment of dermatoses
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物

Also Published As

Publication number Publication date
US6245818B1 (en) 2001-06-12
NO20001087D0 (no) 2000-03-02
WO1999011251A1 (en) 1999-03-11
CA2299366C (en) 2008-04-22
SE9703191D0 (sv) 1997-09-04
DE69810784D1 (de) 2003-02-20
EP1011653A1 (en) 2000-06-28
SE9703191L (sv) 1999-03-05
DK1011653T3 (da) 2003-05-26
AU9098998A (en) 1999-03-22
CA2299366A1 (en) 1999-03-11
ES2191329T3 (es) 2003-09-01
DE69810784T2 (de) 2003-11-13
JP2001514215A (ja) 2001-09-11
SE512531C2 (sv) 2000-03-27
JP3660244B2 (ja) 2005-06-15
AU727349B2 (en) 2000-12-14
EP1011653B1 (en) 2003-01-15
NO20001087L (no) 2000-03-02
ATE230985T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
IL104880A (en) Pharmaceutical composition comprising antigen for autoimmune diseases suppression
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
EP0553291A4 (en) Treatment of autoimmune diseases by oral administration of autoantigens
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
IL113651A0 (en) Pharmaceutical compositions containing alendronate and their use
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
HUP0001237A2 (hu) Módszerek érrendszeri rendellenességek gyógykezeléséhez
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
IS4516A (is) Nýtt lyfjaform
HU883863D0 (en) Process for the preparation of producing and/or portionly form of therapeutical agents
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
MX9706689A (es) Tratamiento de trastornos causados por el factor de crecimiento de citocina.
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
WO2001012166A3 (en) Improved treatment for acute physical insult to the central nervous system
MD1469G2 (ro) Metodă de tratament al şocului combustional
UA30654A (uk) Спосіб лікування посттравматичних дисфункцій висково- нижньощелепового суглоба
RU97116821A (ru) Способ лечения респираторных заболеваний
UA19596A (uk) Спосіб лікуваhhя гіпертоhічhої хвороби гірудорефлексотерапією
RU94043033A (ru) Способ коррекции и модуляции иммуногомеостаза при заболеваниях внутренних органов и нервной системы
UA30125A (uk) Спосіб лікування дітей з ревматоїдним артритом та дифузними хворобами сполучної тканини
UA28644A (uk) Спосіб лікування первинної аменореї центрального генезу у дівчат-підлітків